Vermillion Presents Results Supporting Clinical Utility of Vasclir PAD Test
June 22, 2012
Vermillion Presents Results Supporting Clinical Utility of Vasclir PAD Test
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Sends Quest Notice of Default Alleging Breach of Strategic Alliance Agreement
May 24, 2013 / ProteoMonitor - Vermillion Posts 11 Percent Rise in 2012 Revenues, 8 Percent Uptick in OVA1 Sales
February 22, 2013 / ProteoMonitor - Vermillion Reports Flat Q3 Revenues, First Peer-Reviewed Publication on Vasclir PAD Test
November 16, 2012 / ProteoMonitor - UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Vermillion's Q1 Revenues Decline 28 Percent, CEO Page Stepping Down
May 18, 2012 / ProteoMonitor